Skip to content

US · JBIO · BIOTECHNOLOGY

Jade Biosciences, Inc. (JBIO) intrinsic value and stock valuation

$15.31as of 2026-11-21 · Mkt cap 707.98M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Jade Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values JBIO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from JBIO’s statements →

Jade Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02453 jadebiosciences.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-127.41M
20202025
Free cash flow
-$-94.89M
20202025
Total equity
$332.5M+157.5% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-113.54M-$-74.6M-$-81.41M-$-53.24M-$-23.02M
Net income-$-127.41M-$-69.63M-$-75.52M-$-51.51M-$-22.96M
EPSd-$-4.06M-$-84.91M-$-100.69M-$-73.59M-$-32.8M
Operating cash flow-$-94.69M-$-71.2M-$-56.78M-$-39.12M-$-27.4M
Capital expenditure-$-200K$0.00-$-140K-$-200K-$-180K
Free cash flow-$-94.89M-$-71.2M-$-56.92M-$-39.32M-$-27.58M
Total assets$349.8M$80.3M$127.4M$135.3M$175.4M
Total debt$720K$420K$680K$1.09M$570K
Net debt-$-87.71M-$-33.33M-$-22.82M-$-21.31M-$-53.62M
Total equity$332.5M$76.4M$109.5M$126.7M$172.4M
Cash and short-term investments$336.2M$78.6M$122.4M$129.2M$167.4M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$280K$100K$70K$10K
Gross profit$0.00-$-280K-$-100K-$-70K-$-10K
Research and development expenses$93.1M$53.2M$64.2M$38.6M$15M
Selling, general and administrative expenses$20.4M$21.1M$17.1M$14.6M$8.02M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$113.5M$74.3M$81.3M$53.2M$23M
Cost and expenses$113.5M$74.6M$81.4M$53.2M$23M
Interest income$7.78M$5.04M$5.95M$1.83M$70K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$30K$280K$100K$70K$10K
Ebitda-$-127.33M-$-69.29M-$-75.37M-$-51.42M-$-22.95M
Operating income-$-113.54M-$-74.6M-$-81.41M-$-53.24M-$-23.02M
Total other income/expenses, net-$-13.81M$5.02M$5.94M$1.75M$60K
Income before tax-$-127.35M-$-69.57M-$-75.47M-$-51.49M-$-22.96M
Income tax expense$60K$60K$60K$30K$0.00
Net income-$-127.41M-$-69.63M-$-75.52M-$-51.51M-$-22.96M
Weighted average shares outstanding$31.4M$820K$750K$700K$700K
Weighted average diluted shares outstanding$31.4M$820K$750K$700K$700K
Balance sheet
20252024202320222021
Cash and short-term investments$336.2M$78.6M$122.4M$129.2M$167.4M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$336.2M$80.1M$124.2M$131.5M$174.3M
Property, plant and equipment, net$0.00$210K$900K$1.25M$730K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$13.6M$210K$3.19M$3.8M$1.03M
Total assets$349.8M$80.3M$127.4M$135.3M$175.4M
Accounts payable$2.15M$220K$2.4M$2.58M$1.21M
Short-term debt$0.00$420K$420K$390K$190K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$16.5M$3.83M$17.6M$7.78M$2.55M
Long-term debt$720K$0.00$260K$700K$380K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$720K$70K$320K$780K$400K
Capital lease obligations$720K$0.00$260K$700K$380K
Total liabilities$17.3M$3.9M$18M$8.56M$2.94M
Common stock$10K$0.00$0.00$0.00$0.00
Retained earnings-$-174.39M-$-233.05M-$-163.42M-$-87.9M-$-36.39M
Accumulated other comprehensive income (loss)$130K$100K$240K-$-470K-$-60K
Total equity$332.5M$76.4M$109.5M$126.7M$172.4M
Total investments$247.7M$44.9M$99M$106.8M$113.2M
Total debt$720K$420K$680K$1.09M$570K
Net debt-$-87.71M-$-33.33M-$-22.82M-$-21.31M-$-53.62M
Cash flow statement
20252024202320222021
Net income-$-127.41M-$-69.63M-$-75.52M-$-51.51M-$-22.96M
Depreciation and amortization$30K$280K$100K$70K$10K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-8.2M-$-11.17M$9.8M$7.75M-$-6.51M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$360K-$-2.17M-$-160K$1.37M$610K
Net cash provided by operating activities-$-94.69M-$-71.2M-$-56.78M-$-39.12M-$-27.4M
Investments in property, plant and equipment-$-200K$0.00-$-140K-$-200K-$-180K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-247.01M$56M$11.9M$6.93M-$-113.43M
Common stock issued$360.6M$25.4M$46M$400K$190.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$360.8M$25.4M$46M$400K$190.5M
Net change in cash$54.7M$10.3M$1.09M-$-31.8M$49.6M
Cash at end of period$88.4M$33.8M$23.5M$22.4M$54.2M
Operating cash flow-$-94.69M-$-71.2M-$-56.78M-$-39.12M-$-27.4M
Capital expenditure-$-200K$0.00-$-140K-$-200K-$-180K
Free cash flow-$-94.89M-$-71.2M-$-56.92M-$-39.32M-$-27.58M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Jade Biosciences, Inc.

        Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.

        CEO
        Tom Frohlich
        Employees
        55
        Beta
        1.49

        Explore

        Frequently asked questions

        What is the intrinsic value of Jade Biosciences, Inc. (JBIO)?

        InvestorsCraft does not currently publish an intrinsic value for JBIO. How the IC value is calculated.

        Is JBIO undervalued?

        InvestorsCraft does not publish an undervaluation signal for JBIO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.